FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
Dr Anil Shah discusses how his book Nosecentric helps both patients and surgeons improve communication, set realistic goals, and reduce the risk of revision rhinoplasty.